Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2009, for Croff Enterprises, Inc. (Note: The input metadata referenced "Therapeuticsmd, Inc.", but the filing text explicitly identifies the registrant as Croff Enterprises, Inc.). The Company is classified as a shell company and a smaller reporting company. Following a 2007 spin-off of its oil and gas assets, the Company currently has no active business operations or revenue sources. Management is seeking a merger or business combination with a privately-held operating company.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(29,033) | $(32,681) |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.06) |
| Cash and Cash Equivalents (Ending) | $27,953 | $360,984 |
| Net Cash Used in Operating Activities | $(26,466) | $(7,840) |
| Total Assets | $27,953 | $429,158 |
| Total Liabilities | $38,289 | $84,112 |
| Stockholders' Equity | $(10,336) | $18,697 |
| Debt Outstanding | $0 | $0 |
Liquidity: The Company reported a working capital deficit, with current liabilities of $38,289 exceeding current assets of $27,953. Significant liabilities include $32,076 in dividends payable.
Material Changes vs. Prior Period
- Net Loss Improvement: The net loss decreased by approximately 11% to $(29,033) from $(32,681) in the prior year quarter, primarily due to a reduction in general and administrative expenses from $35,122 to $29,033.
- Cash Position: Cash and cash equivalents declined significantly from $360,984 in March 2008 to $27,953 in March 2009. This reflects the ongoing burn rate of the shell company structure and the absence of operating cash inflows.
- Equity Status: Stockholders' equity turned negative, moving from a surplus of $18,697 in December 2008 to a deficit of $(10,336) by March 31, 2009, driven by the quarterly net loss.
- Interest Income: The Company recorded $0 in interest income for Q1 2009, compared to $2,441 in Q1 2008, reflecting lower cash balances.
Outlook, Risks, and Management Commentary
Going Concern: Management explicitly states that the Company has sustained losses since the 2007 spin-off and requires additional debt or equity financing to fund activities. There is no assurance that such financing will be available.
Operational Outlook: With $27,953 in cash, management believes funds will support minimal operations until approximately December 31, 2009. The primary strategic objective is to secure a merger or business combination.
Risks: If the Company exhausts its funds before completing a merger and cannot secure additional financing, it may be required to discontinue operations entirely or seek protection under federal bankruptcy laws.
Unusual Items: The financial statements reflect a "shell company" status with no revenue. The $32,076 in dividends payable represents a legacy obligation from prior periods.
Investor Verification Checklist
- Company Identity: Verify that the filing pertains to Croff Enterprises, Inc. and not Therapeuticsmd, Inc., as the metadata suggested.
- Liquidity Runway: Confirm the accuracy of the management estimate that cash reserves will last until December 31, 2009, given the current burn rate.
- Dividend Liability: Investigate the status of the $32,076 in dividends payable and any potential legal or financial implications of this outstanding obligation.
- Merger Progress: Assess any recent announcements or filings regarding potential mergers or business combinations, as this is the Company's sole path to value creation.
- Financing Plans: Review for any pending or proposed equity/debt offerings intended to extend the Company's operational life beyond late 2009.